News Exelixis, Inc.

Stocks

EXEL

US30161Q1040

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:00:43 10/07/2026 pm IST			5-day change	1st Jan Change
56.62 ^USD	-0.85%		+1.97%	+29.19%

07/07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT
02/07	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says	MT

All News

Mentions Relevance

07/07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT
02/07	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says	MT
02/07	UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating	MT
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Value-Defensive Index	CI
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Growth-Defensive Index	CI
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Defensive Index	CI
22/06	Exelixis Provides Update on the Phase 3 Stellar-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer	CI
22/06	Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer	BU
09/06	Exelixis, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10:40 AM
03/06	Exelixis, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 11:05 AM
30/05	Exelixis says Cabometyx reduces risk of progression or death by 74% in non-functional net, 60% in functional net	RE
30/05	Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026	BU
30/05	Exelixis Announces Results from Subgroup Analysis of Phase 3 Cabinet Pivotal Trial Evaluating Cabometyx in Non-Functional and Functional Neuroendocrine Tumors At Asco 2026	CI
28/05	Exelixis, Inc. Presents at Bernstein 42nd Annual Strategic Decisions Conference, May-27-2026 03:30 PM
28/05	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June	BU
22/05	Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types	BU
22/05	Exelixis, Inc. Announces Presentations of Cabometyx and Zanzalintinib At 2026 2026 Annual Meeting	CI
21/05	Exelixis, Inc. Presents at Stifel 2026 Targeted Oncology Virtual Forum, May-20-2026 01:30 PM
20/05	Exelixis Insider Sold Shares Worth $1,745,050, According to a Recent SEC Filing	MT
19/05	Exelixis, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 09:00 AM
19/05	Merck to Collaborate With Exelixis on Phase 3 Colorectal Cancer Trial	MT
19/05	Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer	BU
12/05	Exelixis, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10:00 AM
11/05	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May 2026	AQ
11/05	Exelixis Insider Sold Shares Worth $2,742,600, According to a Recent SEC Filing	MT